Summary of Precigen (PGEN) Q1 2026 Earnings Call

1Key Financial Results and Metrics

Net Product Revenue: $21.6 million from PAPZIMEOS, a significant increase from $3.4 million in Q4 2025.

Total Revenue: $23.3 million for Q1 2026.

Operating Loss: $6 million; Net Loss: $7.9 million ($0.02 per share).

Cash Position: $56.7 million in cash, cash equivalents, and investments.

Cash Used in Operations: $43.8 million, including $13 million in non-recurring cash outflows.

Guidance: Expect cash flow breakeven by the end of 2026 without needing additional capital.

2Strategic Updates and Business Highlights

PAPZIMEOS Launch: The therapy has been well-received, with strong uptake across both major medical centers and community practices. Approximately 400 patients are registered in the PAPZIMEOS patient hub, with 25% from community settings.

Payer Coverage: Over 90% of insured lives in the U.S. are covered, enhancing patient access.

Clinical Data: Positive durability and efficacy data expected to be presented at the upcoming ASCO conference.

Regulatory Initiatives: Plans to initiate a pediatric trial for PAPZIMEOS in Q4 2026 and ongoing marketing authorization application with EMA.

PRGN-2009 Development: Immunotherapy targeting HPV-related cancers is advancing in Phase II trials.

3Forward Guidance and Outlook

Q2 Expectations: Anticipated continued revenue growth driven by increasing patient enrollment and treatment uptake. While specific guidance for Q2 revenue was not provided, management expressed confidence in ongoing positive trends.

Long-term Outlook: The company aims for sustained growth through expanding the patient base and enhancing treatment accessibility, particularly with the recent assignment of a permanent J-code.

4Bad News, Challenges, or Points of Concern

Operating Loss: Despite revenue growth, the company reported a significant operating loss, indicating ongoing expenses related to commercialization efforts.

Cash Flow: High cash used in operations raises concerns about financial sustainability, although management reassured that this is expected to improve in future quarters.

Market Competition: The potential for competitive pressures in the therapeutic landscape for RRP and HPV-related cancers was not explicitly addressed but remains a consideration.

5Notable Q&A Insights

Patient Treatment Progress: Management did not disclose specific numbers of patients treated but indicated that they are beginning to see patients complete the full course of therapy.

Redosing Trial: Ongoing trials for redosing patients are focused on those with partial responses, with data expected to be shared in the future.

Hub Conversion: Management is monitoring the conversion of patients in the hub to commercial products but indicated that definitive details would take more time to assess.

Durability Data at ASCO: Anticipated data is expected to support further label expansions and enhance the understanding of the therapy's efficacy. Overall, Precigen's Q1 2026 results reflect a strong start for PAPZIMEOS, with significant revenue growth and positive market reception, although challenges related to operating losses and cash flow management remain.